Compare Illumina, Inc. (ILMN) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Uranium Energy Corp — how do they compare? Illumina, Inc. trades at $189.82 (market cap $27.94B), while Uranium Energy Corp trades at $9.6 (market cap $4.65B). The key difference: Illumina, Inc. is far larger — about 6× Uranium Energy Corp's market cap, and Illumina, Inc. is trading nearer its 52-week high, Uranium Energy Corp nearer its low. Which is the better fit depends on your goals.
| ILMN | UEC | |
|---|---|---|
Market Cap | $27.94B | $4.65B |
Sector | Health | Energy |
52-Week High | $194.33 | $20.14 |
52-Week Low | $91.00 | $8.00 |
Enterprise Value | $29.33B | $4.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
UEC trades at $9.40, up 1.29% today, but faces bearish technical signals with 18 sell indicators against 2 buys. The company reported a net loss of $87.66 million in 2025 on $66.84 million revenue, with a negative net margin of -513.24% in 2026. Recent news highlights operational challenges, including zero sales in Q3 2026 and wider losses, though strategic assets and $794 million liquidity offer some stability.
Despite analyst consensus favoring buys (87.5%), high execution risks and persistent losses temper near-term optimism. Investment appeal hinges on successful production ramp-up and uranium price recovery, but volatility and cost pressures present significant downside risks for stockholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
